The Study of Pharmacological Treatment Pattern for Cannabis-induced Psychosis

The Study of Pharmacological Treatment Pattern for Cannabis-induced Psychosis

A cross-sectional and retrospective chart review study was conducted at the Princess Mother National Institute on Drug Abuse Treatment (PMNIDAT), Thailand. All patients who admitted at PMNIDAT from October 2013 to September 2019 were included. Patients aged 18-65 years who met the International Classification of Disease-10 (ICD-10) criteria of CIP and Had a positive urine test of cannabis were included. Cannabis use is a component cause of psychosis.More than half of symptoms of cannabis-induced psychosis (CIP) were hallucination, delusion, irritable and anxiety. Antipsychotic drug was still a key psychotropic drugs for treatment of CIP. However, antidepressants and benzodiazepines were commonly used for treatment of other symptoms beyond psychotics

Inclusion Criteria:

• Patients ≥ 12 years of age
• Patients who had been diagnosed as Cannabis-induced psychosis by International statistical Classification of Disease and Related Health problem (ICD-10) on 2016 code F12.5
• Patients had history of use of cannabis in medical chart
• Patients had the positive urine screening test of cannabis at the first day of admission

Exclusion Criteria:

• Patients had psychosis from organic psychosis, defined by diagnosis by ICD-10 code F09.6
• Unavailable data for evaluate of outcome especially data of drug use, content of drug use or urine screening test
• Patients who cancel of medical treatment before 7 day after admission.